Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026

STX-1150 is currently being evaluated in a first-in-human Phase 1 trial in adults with elevated LDL cholesterol and increased cardiovascular risk.

Rhea-AI Summary

Scribe Therapeutics (Nasdaq: SCTX) will present preclinical findings from its cholesterol-targeting programs at AHA Scientific Sessions on November 7, 2026.

The STX-1150 presentation will report persistent LDL cholesterol control for at least two years after a single dose in non-human primates. The therapy is designed to repress PCSK9 without permanently changing the underlying DNA sequence. A second presentation will describe durable lipoprotein(a) reduction across preclinical models after a single administration of the STX-1200 prototype, which targets the LPA gene in the liver.

3 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointSTX-1150 is being evaluated in a first-in-human Phase 1 trial in adults with elevated LDL-C and increased cardiovascular risk.
• Minor pointSTX-1150 preclinical findings show persistent LDL cholesterol control for at least two years after one dose in non-human primates.
• Minor pointSTX-1200 prototype preclinical data show durable lipoprotein(a) reduction across models after a single administration.

Negative

• None.

News Explained

Scribe says STX-1150 is being evaluated in a first-in-human Phase 1 trial, while the AHA presentation will report preclinical data.

Argus 15 min delay 10 alerts

+2.04% vs previous close $16.53 last price 1.8x rel. volume Open Argus

Details

Market Reaction – SCTX

+3.1% Peak in 20 min

$16.08 – $17.48 Day Range

$312.94M Mkt Cap at Last Price

On Nov 4, the day this news came out, the latest delayed price for SCTX is 2.04% above the previous close. Argus tracked a peak move of +3.1% during the session. Our momentum scanner has recorded 10 alerts for this stock so far that day. The latest delayed price is $16.53. Relative volume is above average at 1.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

LDL-C control duration: At least two years after a single dose

LDL-C control duration

At least two years after a single dose

STX-1150 preclinical data in non-human primates

Historical Context

1 past event · Latest: Sep 02

1 event

1. Sep 02

   Phase 1 trial

   24h Move

   -0.3%

   Initiated the first-in-human Phase 1 trial of STX-1150, the same LDL-C-lowering program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pcsk9, ldl-c, lipoprotein(a), ascvd, +2 more

6 terms

pcsk9 medical

"designed to repress PCSK9 without permanently altering the underlying DNA sequence"

PCSK9 is a protein made in the body that controls how many 'bad' cholesterol receptors remain on liver cells, acting like a gatekeeper that determines how much LDL cholesterol is cleared from the blood. It matters to investors because medicines that block PCSK9 can sharply lower cholesterol and reduce heart risk, creating large markets, regulatory milestones, and patent/value drivers for drug developers and healthcare portfolios.

ldl-c medical

"persistent LDL-C control for at least two years in non-human primates"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

lipoprotein(a) medical

"durable reduction of lipoprotein(a) [Lp(a)] across preclinical models"

Lipoprotein(a) is a blood particle that carries cholesterol and has an extra protein tag, making it more likely than ordinary cholesterol to promote plaque build-up in arteries; levels are largely inherited and vary little with diet. Investors care because high levels are a clear marker of heart disease risk, driving demand for diagnostics, specialized drugs and regulatory attention—factors that can affect valuations and future sales for companies developing tests or treatments.

ascvd medical

"key lipid drivers of atherosclerotic cardiovascular disease (ASCVD)"

Atherosclerotic cardiovascular disease (ASCVD) is the condition where fatty deposits build up inside arteries, narrowing blood flow to the heart or brain much like mineral scale clogs a pipe. It matters to investors because treatments, diagnostics, and preventive measures for ASCVD drive large markets, influence healthcare costs and insurance payouts, and affect regulatory and clinical trial outcomes that can materially change a company’s revenue prospects.

phase 1 trial regulatory

"evaluated in a first-in-human Phase 1 trial"

Phase 1 trial is the first stage of testing a new drug or treatment in humans, focused mainly on safety, tolerability and finding the right dose, usually in a small group of volunteers or patients. For investors it matters because clear safety and dosing results reduce development risk, unlock later, larger trials, and can meaningfully change a biotech’s value and timeline — like a prototype’s maiden test flight that shows whether further investment makes sense.

crispr technical

"a CRISPR-based investigational gene editing therapy"

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials

A second presentation will reveal enhanced potency and specificity preclinical data for STX-1200, Scribe’s gene editing program designed to lower lipoprotein(a)

CEO to participate in the inaugural AHA Innovation Forum’s sessions on entrepreneurship and AI in cardiovascular innovation

ALAMEDA, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced its participation in the American Heart Association’s Scientific Sessions taking place in Chicago, IL, from November 6-9, 2026.

Scribe will deliver two presentations, one of which is a late-breaking presentation, and participate in two sessions featured in the inaugural AHA Innovation Forum. The presentations will feature preclinical data from two of Scribe’s three programs targeting key lipid drivers of atherosclerotic cardiovascular disease (ASCVD):

• In the late-breaking presentation, Scribe will report that a single dose of STX-1150 provides persistent LDL cholesterol (LDL-C) control for at least two years in non-human primates. STX-1150 is an epigenetic silencing therapy designed to repress PCSK9 without permanently altering the underlying DNA sequence. It is currently being evaluated in a first-in-human Phase 1 trial in adults with elevated LDL-C and increased cardiovascular risk.
• Scribe’s second presentation will highlight data showing that a single administration of the STX-1200 prototype, a CRISPR-based investigational gene editing therapy, achieves robust and durable reduction of lipoprotein(a) [Lp(a)] across preclinical models. By editing the LPA gene in the liver, STX-1200 is designed to durably lower Lp(a), a major genetic risk factor for ASCVD.

Additional details on these events are listed below and on the AHA website.

Scientific Presentations

Late-breaking presentation title: STX-1150 Provides Persistent LDL-C Control For At Least Two Years After A Single Dose, A Novel Epigenetic Silencing Approach
Session: Late-Breaking Abstracts in Atherosclerosis, Thrombosis, and Vascular Biology
Date: Saturday, Nov. 7, 2026
Time: 10:45 AM CT
Speaker: Benjamin Oakes, Ph.D., Co-founder and CEO

Presentation title: A Single Administration of STX-1200 CRISPR-CasX Gene Editor Achieves Robust and Durable Reduction of Lipoprotein(a) Across Preclinical Models
Session: Precision Cardiovascular Genetics: Improving Therapy and Prognosis
Date: Saturday, Nov. 7, 2026
Time: 11:06 AM CT
Speaker: Elena Smekalova, Ph.D., Associate Director, Discovery Biology

AHA Innovation Forum

Session I: The Entrepreneur's Journey: From Idea to Impact
Date: Friday, Nov. 6, 2026
Time: 8:05 - 8:55 AM CT
Speaker: Benjamin Oakes, Ph.D., Co-founder and CEO

Session IV: Fireside Conversation: AI and the Future of Cardiovascular Innovation
Date: Friday, Nov. 6, 2026
Time: 11:15 AM - 12:05 PM CT
Speaker: Benjamin Oakes, Ph.D., Co-founder and CEO

About Scribe Therapeutics Inc.

Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.

Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com

Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How long did Scribe Therapeutics' STX-1150 control LDL cholesterol in preclinical testing?

A single dose of STX-1150 provided persistent LDL cholesterol control for at least two years in non-human primates. The findings will be presented in a late-breaking session at AHA Scientific Sessions on November 7, 2026.

Is Scribe Therapeutics' STX-1150 being tested in humans?

STX-1150 is currently being evaluated in a first-in-human Phase 1 trial in adults with elevated LDL cholesterol and increased cardiovascular risk. The durability findings scheduled for presentation at AHA are from non-human primates, not that human trial.